AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8123409 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 2 mg kg‐1 + Suxamethonium 1 mg kg‐1
Number of subjects: 43
Study 8123409 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 4 mg kg‐1 + Suxamethonium 1 mg kg‐1
Number of subjects: 43
Study 8123409 — intervention group
Group type: COMPARATOR
Intervention: No thiopentone or suxamethonium (group N)
Number of subjects: 43
Study 3541813 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 80
Study 3541813 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 80
Study 31899928 — intervention group
Group type: EXPERIMENTAL
Intervention: TORA training during NRP course
Number of subjects: 65
Study 31899928 — intervention group
Group type: COMPARATOR
Intervention: Standard NRP course (control)
Number of subjects: 65
Study 31751354 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter Strike: Global Offensive
Number of subjects: 18
Study 27865532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarp-assisted cooling (water temperature 9.20°C)
Number of subjects: 2
Study 27865532 — intervention group
Group type: COMPARATOR
Intervention: Passive cooling in a climatic chamber
Number of subjects: 2
Study 26685030 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adipose derived mesenchymal stem cell treatment
Number of subjects: 40
Study 26685030 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic microfracture alone (control group)
Number of subjects: 40
Study 22776420 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD patients
Number of subjects: 45
Study 22776420 — intervention group
Group type: COMPARATOR
Intervention: Trauma controls (TCs)
Number of subjects: 45
Study 22776420 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 45
Study 21873086 — intervention group
Group type: EXPERIMENTAL
Intervention: MTAD
Number of subjects: 45
Study 21873086 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA
Number of subjects: 45
Study 21873086 — intervention group
Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 45
Study 18266604 — intervention group
Group type: EXPERIMENTAL
Intervention: HGS004 (40 mg/kg)
Number of subjects: 63
Study 18266604 — intervention group
Group type: EXPERIMENTAL
Intervention: HGS004 (8, 20, and 40 mg/kg)
Number of subjects: 63
Study 18266604 — intervention group
Group type: EXPERIMENTAL
Intervention: HGS004 (0.4-40 mg/kg)
Number of subjects: 63
Study 18266604 — intervention group
Group type: EXPERIMENTAL
Intervention: HGS004
Number of subjects: 63
Study 18266604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 17304769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation (TH-I)
Number of subjects: 45
Study 17304769 — intervention group
Group type: COMPARATOR
Intervention: Conservative rehabilitation (TH-C)
Number of subjects: 45
Study 15541412 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIDFORM administered 0‐30 min precoitus
Number of subjects: 20
Study 15541412 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIDFORM given 8‐10 h precoitus
Number of subjects: 20
Study 15541412 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% nonoxynol‐9 (N‐9) product administered 0‐30 min precoitus
Number of subjects: 20
Study 15541412 — intervention group
Group type: COMPARATOR
Intervention: Control cycles (no treatment)
Number of subjects: 20
Study 11416735 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Treatment Interruptions (STI)
Number of subjects: 10
Study 9285375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/kg)
Number of subjects: 40
Study 9285375 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo (0.9% NaCl) followed by intravenous midazolam (0.05 mg/kg)
Number of subjects: 40
Study 8417420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 102
Study 8417420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 102
Study 8417420 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 102
Study 8417420 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanate
Number of subjects: 102
Study 8417420 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 102
Study 8417420 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 102
Study 3734847 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy and radiotherapy
Number of subjects: 12
Study 31544519 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive norm messaging with haptic input
Number of subjects: 0
Study 31544519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no descriptive norm messaging)
Number of subjects: 0
Study 30156200 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP followed by Er, Cr: YSGG laser treatment
Number of subjects: 40
Study 30156200 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 40
Study 26363048 — intervention group
Group type: EXPERIMENTAL
Intervention: mCare mobile application
Number of subjects: 95
Study 25093276 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet combining lower carbohydrate content and glycemic index (GI)
Number of subjects: 25
Study 25093276 — intervention group
Group type: COMPARATOR
Intervention: Diet combining higher carbohydrate content and glycemic index (GI)
Number of subjects: 25
Study 25093276 — intervention group
Group type: COMPARATOR
Intervention: Diets varying in protein content and glycemic index
Number of subjects: 25
Study 25093276 — intervention group
Group type: COMPARATOR
Intervention: Controlled lab study with four diets differing in carbohydrate content and glycemic index
Number of subjects: 25
Study 22718189 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroalbuminuria (1.48%)
Number of subjects: 37
Study 22718189 — intervention group
Group type: COMPARATOR
Intervention: Normal albuminuria (27.4%)
Number of subjects: 37
Study 22718189 — intervention group
Group type: COMPARATOR
Intervention: Microalbuminuria (27.2%)
Number of subjects: 37
Study 22718189 — intervention group
Group type: EXPERIMENTAL
Intervention: Podocyte detachment
Number of subjects: 37
Study 22718189 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial cell fenestration
Number of subjects: 37
Study 21092500 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve blockade (CFNB) with ropivacaine 0.2% (median infusion rate 5 ml/h)
Number of subjects: 126
Study 21092500 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous analgesia (CIA) with fentanyl 30 µg/kg (2 ml/h)
Number of subjects: 126
Study 19012865 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility testing for AD with APOE epsilon 4+
Number of subjects: 123
Study 19012865 — intervention group
Group type: COMPARATOR
Intervention: Deterministic genetic testing (positive results)
Number of subjects: 123
Study 16422868 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (Viagra)
Number of subjects: 0
Study 16422868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12902634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-permeability hemofiltration
Number of subjects: 28
Study 12902634 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemofiltration
Number of subjects: 28
Study 12902634 — intervention group
Group type: EXPERIMENTAL
Intervention: High-permeability filtrates
Number of subjects: 28
Study 12902634 — intervention group
Group type: COMPARATOR
Intervention: Conventional filtrates
Number of subjects: 28
Study 11381293 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic angiogenesis using basic fibroblast growth factor
Number of subjects: 0
Study 11381293 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic angiogenesis using human vascular endothelial growth factor
Number of subjects: 0
Study 9142006 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg)
Number of subjects: 28
Study 9142006 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg)
Number of subjects: 28
Study 9142006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7704492 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin and aztreonam (antibiotic prophylaxis)
Number of subjects: 200
Study 7704492 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 200
Study 3555429 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation
Number of subjects: 0
Study 3555429 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes
Number of subjects: 0
Study 29154650 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicago School Readiness Project (CSRP) preschool intervention
Number of subjects: 602
Study 29154650 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 602
Study 25386694 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning course
Number of subjects: 98
Study 25386694 — intervention group
Group type: COMPARATOR
Intervention: lecture-based course
Number of subjects: 98
Study 24743455 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua lymphatic therapy (ALT) combined with home-based exercise (n = 13)
Number of subjects: 25
Study 24743455 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise alone (control group; n = 12)
Number of subjects: 25
Study 23354227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved RBCs
Number of subjects: 57
Study 23354227 — intervention group
Group type: COMPARATOR
Intervention: Refrigerated RBCs
Number of subjects: 57
Study 21353109 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (administered orally for 4 weeks before IUI)
Number of subjects: 98
Study 21353109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 21353109 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 98
Study 21353109 — intervention group
Group type: COMPARATOR
Intervention: Antibody-negative group
Number of subjects: 98
Study 18808400 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 167
Study 18808400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 16670077 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant erythropoietin (epoietin) + granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 21
Study 16670077 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 12814500 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction message
Number of subjects: 2027
Study 12814500 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-effects message
Number of subjects: 2027
Study 12814500 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 2027
Study 12814500 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary abstinence message
Number of subjects: 2027
Study 10836911 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily subcutaneous ardeparin (100 anti‐Xa IU/kg of body weight)
Number of subjects: 1195
Study 10836911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1195
Study 8780079 — intervention group
Group type: EXPERIMENTAL
Intervention: Zalcitabine monotherapy (2.25 mg/day)
Number of subjects: 79
Study 8780079 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (2.25 mg/day ddC with zidovudine)
Number of subjects: 79
Study 8780079 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 79
Study 1345754 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 212
Study 1345754 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 212
Study 31638608 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (1 mg/kg of weight)
Number of subjects: 60
Study 31638608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28132867 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg GS-9256 BID
Number of subjects: 54
Study 28132867 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg GS-9256 QD
Number of subjects: 54
Study 28132867 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg GS-9256 BID
Number of subjects: 54
Study 28132867 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 54
Study 25424973 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology interventions (random assignment to one out of nine interventions)
Number of subjects: 165
Study 24392703 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 3 months
Number of subjects: 27
Study 21543993 — intervention group
Group type: COMPARATOR
Intervention: 0.03% mitomycin C (MMC)
Number of subjects: 38
Study 21543993 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (1.25 mg in 0.05 mL)
Number of subjects: 38
Study 21543993 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab soaked in sponges (1.25 mg in 0.05 mL)
Number of subjects: 38
Study 19733018 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (oral ingestion of therapeutic THC)
Number of subjects: 117
Study 19733018 — intervention group
Group type: COMPARATOR
Intervention: Illicit plant cannabis product (smoking)
Number of subjects: 117
Study 17717037 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 22
Study 17717037 — intervention group
Group type: COMPARATOR
Intervention: Medical management with thrombolytic drugs
Number of subjects: 22
Study 16379317 — intervention group
Group type: EXPERIMENTAL
Intervention: TURN treatment
Number of subjects: 12
Study 16379317 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG therapy (6 intravesical instillations of Onko BCG)
Number of subjects: 12
Study 16379317 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study 12509214 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic red blood cells (n = 15)
Number of subjects: 31
Study 12509214 — intervention group
Group type: COMPARATOR
Intervention: Predeposited autologous whole blood transfusion (n = 16)
Number of subjects: 31
Study 9609216 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (20,500 AXa IU/ml) once daily
Number of subjects: 0
Study 9609216 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin (10,250 AXa IU/ml) twice daily
Number of subjects: 0
Study 7891796 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 73
Study 7891796 — intervention group
Group type: COMPARATOR
Intervention: Conventional drugs
Number of subjects: 73
Study 2226079 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct current therapy
Number of subjects: 50
Study 2226079 — intervention group
Group type: COMPARATOR
Intervention: Bipolar diathermy
Number of subjects: 50
Study 389265 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Bacille Calmette‐Guérin vaccine (BCG)
Number of subjects: 32
Study 389265 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 32
Study 31318176 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 0
Study 31318176 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 0
Study 28917544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-45 mg)
Number of subjects: 3028
Study 28917544 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylureas (5-15 mg glibenclamide, 2-6 mg glimepiride, or 30-120 mg gliclazide)
Number of subjects: 3028
Study 28917544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3028
Study 28917544 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylureas
Number of subjects: 3028
Study 28917544 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 3028
Study 25775445 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of 25 U of BoNT‐A to the masseter muscle bilaterally (Group I)
Number of subjects: 20
Study 25775445 — intervention group
Group type: EXPERIMENTAL
Intervention: Two sessions of 25 U of BoNT‐A to the masseter muscle bilaterally (Group II)
Number of subjects: 20
Study 23720105 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 96
Study 23720105 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 96
Study 21746787 — intervention group
Group type: EXPERIMENTAL
Intervention: C+P (25 g carbohydrate + 10 g whey protein)
Number of subjects: 10
Study 21746787 — intervention group
Group type: COMPARATOR
Intervention: CHO (25 g carbohydrate)
Number of subjects: 10
Study 21746787 — intervention group
Group type: EXPERIMENTAL
Intervention: C+P
Number of subjects: 10
Study 21746787 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 10
Study 19309533 — intervention group
Group type: EXPERIMENTAL
Intervention: Approaching targets
Number of subjects: 0
Study 19309533 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding targets
Number of subjects: 0
Study 19309533 — intervention group
Group type: EXPERIMENTAL
Intervention: Model simple and complex cells responses
Number of subjects: 0
Study 19309533 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze direction
Number of subjects: 0
Study 16952635 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg tramadol/650 mg acetaminophen orally plus periprostatic 1% lidocaine
Number of subjects: 60
Study 16952635 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus periprostatic 1% lidocaine
Number of subjects: 60
Study 15252826 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for the first 4 weeks and 10 mg/day for the following 4 weeks)
Number of subjects: 8
Study 15252826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11236074 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 30
Study 11236074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 30
Study 11236074 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine and Sertraline
Number of subjects: 30
Study 11236074 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 30
Study 11236074 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with first depression
Number of subjects: 30
Study 9294750 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 81
Study 9294750 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 81
Study 9294750 — intervention group
Group type: COMPARATOR
Intervention: Cervical Collar
Number of subjects: 81
Study 8420311 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally administered 17 beta‐estradiol
Number of subjects: 127
Study 8420311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 3736737 — intervention group
Group type: COMPARATOR
Intervention: Ibopamine, 200 mg and 600 mg
Number of subjects: 20
Study 3736737 — intervention group
Group type: COMPARATOR
Intervention: Indoramin, 50 mg
Number of subjects: 20
Study 31810613 — intervention group
Group type: COMPARATOR
Intervention: PMMA
Number of subjects: 21
Study 31810613 — intervention group
Group type: EXPERIMENTAL
Intervention: POM
Number of subjects: 21
Study 31810613 — intervention group
Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 21
Study 28657911 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (n = 19)
Number of subjects: 38
Study 28657911 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 19)
Number of subjects: 38
Study 27098150 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 6098
Study 27098150 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab/Lapatinib combination
Number of subjects: 6098
Study 26238121 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat 0.7 mg/kg BIW
Number of subjects: 116
Study 26238121 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat 1.0 mg/kg BIW
Number of subjects: 116
Study 26238121 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat 1.5 mg/kg BIW
Number of subjects: 116
Study 26238121 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat 2.0 mg/kg BIW
Number of subjects: 116
Study 26238121 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat 2.0 mg/kg TIW
Number of subjects: 116
Study 26238121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 23445604 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week self-management workshop
Number of subjects: 134
Study 23445604 — intervention group
Group type: COMPARATOR
Intervention: Information-only intervention
Number of subjects: 134
Study 21123458 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 mg choline/d
Number of subjects: 23
Study 21123458 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100 mg choline/d
Number of subjects: 23
Study 18355770 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (L-T4) treatment
Number of subjects: 226
Study 18355770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 16310388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg once daily
Number of subjects: 529
Study 16310388 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 88 microg twice daily
Number of subjects: 529
Study 14567443 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (11/h)
Number of subjects: 16
Study 14567443 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 16
Study 10854867 — intervention group
Group type: EXPERIMENTAL
Intervention: Speculoscopy
Number of subjects: 1150
Study 10854867 — intervention group
Group type: COMPARATOR
Intervention: Acetic Acid Test (AAT)
Number of subjects: 1150
Study 9088581 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg sotalol alone (phase 1)
Number of subjects: 6
Study 9088581 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg sotalol plus 20 ml of antacid (phase 2)
Number of subjects: 6
Study 9088581 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg sotalol plus antacid given 2 h after sotalol (phase 3)
Number of subjects: 6